Clinical Trial Update: A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma [Phase 4]

View source ↗

Summary

Phase 4 trial assessing 3 months of latanoprost to reduce intraocular pressure in ocular hypertension or open-angle glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle
• Ocular Hypertension

Drugs mentioned

• Latanoprost (Latanoprost)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Status: COMPLETED